RU2432357C2 - ПОЛИПЕПТИДЫ НЕТИПИРУЕМОЙ Haemophilus influenzae - Google Patents
ПОЛИПЕПТИДЫ НЕТИПИРУЕМОЙ Haemophilus influenzae Download PDFInfo
- Publication number
- RU2432357C2 RU2432357C2 RU2006144093/10A RU2006144093A RU2432357C2 RU 2432357 C2 RU2432357 C2 RU 2432357C2 RU 2006144093/10 A RU2006144093/10 A RU 2006144093/10A RU 2006144093 A RU2006144093 A RU 2006144093A RU 2432357 C2 RU2432357 C2 RU 2432357C2
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- antibody
- medicine
- influenzae
- polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 10
- 241000606768 Haemophilus influenzae Species 0.000 title claims abstract 4
- 229940047650 haemophilus influenzae Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 5
- 206010033078 Otitis media Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000028993 immune response Effects 0.000 claims abstract 2
- 230000002163 immunogen Effects 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010014568 Empyema Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001606 epiglottitis Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
(57) Изобретение относится к биотехнологии. Описаны полипептиды, вызывающие иммунный ответ против Н. influenzae. Предложено антитело, селективно связывающее указанные полипептиды. Изобретение также относится к иммуногенной композиции, содержащей описанные полипептиды. Изобретение может быть использовано в медицине для лечения или профилактики заболевания и/или инфекции, вызванных H.influenzae, таких как средний отит. 4 н. и 5 з.п. ф-лы, 3 табл.
Description
Claims (9)
1. Полипептид, вызывающий иммунный ответ против Н.influenzae, содержащий аминокислотную последовательность, имеющую идентичность последовательности, составляющую, по меньшей мере, 90%, по отношению к одной или более из SEQ ID NO:1566, 1570, 1938, 2368, 3310, 3520, 5088, 5089 и 5090.
2. Полипептид по п.1, применимый в качестве лекарственного средства.
3. Антитело, селективно связывающееся с полипептидом по п.1 или 2, полученное иммунизацией млекопитающего полипептидом по п.1 или 2.
4. Антитело по п.3, причем антитело представляет собой моноклональное антитело.
5. Антитело по п.3 или 4, применимое в качестве лекарственного средства.
6. Иммуногенная композиция, содержащая (а) полипептид и/или антитело по любому из предшествующих пунктов; и (b) фармацевтически приемлемый носитель.
7. Композиция по п.6, дополнительно содержащая адъювант вакцины.
8. Применение полипептида или антитела по любому из пп.1-5 в производстве лекарственного препарата для лечения или профилактики заболевания и/или инфекции, вызванных Н.influenzae.
9. Применение по п.8 для профилактики среднего отита, бронхита, конъюнктивита, синусита, инфекции мочевых путей, пневмонии, бактериемии, септического артрита, эпиглоттита, эмпиемы, перикардита, целлюлита, остеомиелита или менингита.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0410866.8A GB0410866D0 (en) | 2004-05-14 | 2004-05-14 | Haemophilius influenzae |
GB0410866.8 | 2004-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006144093A RU2006144093A (ru) | 2008-06-20 |
RU2432357C2 true RU2432357C2 (ru) | 2011-10-27 |
Family
ID=32527109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006144093/10A RU2432357C2 (ru) | 2004-05-14 | 2005-05-16 | ПОЛИПЕПТИДЫ НЕТИПИРУЕМОЙ Haemophilus influenzae |
Country Status (10)
Country | Link |
---|---|
US (4) | US7749518B2 (ru) |
EP (5) | EP2351774A1 (ru) |
JP (2) | JP2008506364A (ru) |
CN (1) | CN1997663A (ru) |
BR (1) | BRPI0511118A (ru) |
CA (1) | CA2566632A1 (ru) |
GB (1) | GB0410866D0 (ru) |
IN (1) | IN2015KN00290A (ru) |
RU (1) | RU2432357C2 (ru) |
WO (1) | WO2005111066A2 (ru) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100473663C (zh) * | 2000-02-28 | 2009-04-01 | 启龙股份公司 | 奈瑟球菌蛋白质的异源表达 |
AU2003274511B2 (en) * | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
AU2006235045A1 (en) * | 2005-03-30 | 2006-10-19 | J. Craig Venter Institute, Inc. | Haemophilus influenzae type b |
EP1899366A2 (en) | 2005-06-16 | 2008-03-19 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
KR20080042865A (ko) | 2005-08-10 | 2008-05-15 | 아르네 포르스그렌 아베 | 모락셀라 카타랄리스와 상피세포, 세포외기질 단백질 및보체계의 상호작용 |
CA2636566C (en) | 2006-01-17 | 2018-03-13 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
US9132183B2 (en) * | 2007-03-09 | 2015-09-15 | Newport Laboratories | Modified live (JMSO strain) Haemophilus parasuis vaccine |
US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
US20100189737A1 (en) * | 2008-12-17 | 2010-07-29 | Arico Beatrice | Meningococcal vaccines including hemoglobin receptor |
US8617574B2 (en) * | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
RS63817B1 (sr) | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
EP4119155A1 (en) | 2010-08-31 | 2023-01-18 | GlaxoSmithKline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
US20140286977A1 (en) * | 2011-05-11 | 2014-09-25 | Riesbeck Healthcare Sweden Ab | Protein F - A Novel Haemophilus Influenzae Adhesin with Laminin and Vitronectin binding Properties |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
JP2014520806A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Rna分子の送達のための有用なn:p比を有するリポソーム |
MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
US10279026B2 (en) * | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
EP3804749A3 (en) * | 2012-04-26 | 2021-07-28 | GlaxoSmithKline Biologicals S.A. | Antigens and antigen combinations |
RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
EA030650B1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
ES2908827T3 (es) | 2013-12-19 | 2022-05-04 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
JP6778175B2 (ja) | 2014-07-16 | 2020-10-28 | ノバルティス アーゲー | 脂質ナノ粒子ホスト中に核酸を封入する方法 |
AU2015307324B2 (en) * | 2014-08-27 | 2020-02-06 | Switchfloat Holdings Limited | An oil field tubular and an internal sleeve for use therewith, and a method of deactivating a float valve within the oil field tubular |
CN107072946B (zh) | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
EP3650043A3 (en) * | 2015-06-09 | 2020-07-29 | The Board of Regents of the University of Oklahoma | Compositions and treatments for haemophilus influenzae |
US20180207067A1 (en) | 2015-07-14 | 2018-07-26 | Research Institute at Nationwide Children's Hospit al | Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity |
CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
EP3450446A1 (en) * | 2016-04-27 | 2019-03-06 | Biocells (Beijing) Biotech Co., Ltd. | Treatment method for excitatory neurotoxicity-related injury |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
JP7514621B2 (ja) | 2017-01-04 | 2024-07-11 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Dnabiiワクチンおよび強化された活性を有する抗体 |
AU2018206560A1 (en) * | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
US20180221468A1 (en) * | 2017-01-19 | 2018-08-09 | Iowa State University Research Foundation, Inc. | Haemophilus influenzae immunogen |
WO2018170178A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
WO2020174044A1 (en) * | 2019-02-27 | 2020-09-03 | Evaxion Biotech Aps | Vaccines targeting h. influenzae |
US20230212625A1 (en) * | 2020-02-28 | 2023-07-06 | Trait Biosciences, Inc. | Novel Systems, Methods, And Compositions For The Glycosylation Of Cannabinoid Compounds |
WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
EP4387596A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
CN114574456B (zh) * | 2022-03-18 | 2022-08-12 | 华南理工大学 | 一种亚硝酸盐还原酶突变体及其编码基因和应用 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB234768A (en) * | 1924-05-28 | 1925-08-27 | Ritter Dental Mfg Company Inc | Improvements in adjustable brackets for supporting head-rests or other articles |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
JPH04500203A (ja) | 1988-08-25 | 1992-01-16 | ザ リポソーム カンパニー,インコーポレイテッド | インフルエンザワクチンおよび新規なアジュバント |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6245337B1 (en) * | 1994-08-25 | 2001-06-12 | Washington University | Haemophilus adherence and penetration proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
IL137809A0 (en) | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
PT1126876E (pt) | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Sistemas adjuvantes e vacinas |
EP1880735A3 (en) | 1999-03-19 | 2008-03-12 | GlaxoSmithKline Biologicals S.A. | Vaccine |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
CO5200838A1 (es) | 1999-09-24 | 2002-09-27 | Smithkline Beecham Corp | Vacunas |
CA2396871A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
PT2270171E (pt) | 2000-10-02 | 2013-11-05 | Id Biomedical Corp Quebec | Antigénios de haemophilus influenzae e fragmentos de adn correspondentes |
GB0026002D0 (en) * | 2000-10-24 | 2000-12-13 | Smithkline Beecham Biolog | Novel compounds |
EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
GB0109289D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Novel compounds |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
EP1409013B1 (en) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
WO2003024481A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
GB0200025D0 (en) * | 2002-01-02 | 2002-02-13 | Glaxosmithkline Biolog Sa | Novel compounds |
US20060068386A1 (en) * | 2002-03-04 | 2006-03-30 | Alexei Slesarev | Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof |
CA2796381A1 (en) * | 2003-03-06 | 2004-09-16 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
EP1899366A2 (en) | 2005-06-16 | 2008-03-19 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
CA2636566C (en) | 2006-01-17 | 2018-03-13 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
AT507024B1 (de) | 2008-06-30 | 2011-10-15 | Coil Holding Gmbh | Drosselspule für elektrische energieversorgungsnetze mit reduzierten schallemissionen |
US9018858B2 (en) | 2008-09-24 | 2015-04-28 | B/E Aerospace, Inc. | Calibration method for LED lighting systems |
-
2004
- 2004-05-14 GB GBGB0410866.8A patent/GB0410866D0/en not_active Ceased
-
2005
- 2005-05-16 CN CNA2005800238288A patent/CN1997663A/zh active Pending
- 2005-05-16 IN IN290KON2015 patent/IN2015KN00290A/en unknown
- 2005-05-16 WO PCT/IB2005/001775 patent/WO2005111066A2/en active Application Filing
- 2005-05-16 EP EP10190390A patent/EP2351774A1/en not_active Withdrawn
- 2005-05-16 CA CA002566632A patent/CA2566632A1/en not_active Abandoned
- 2005-05-16 EP EP10190381A patent/EP2351773A1/en not_active Withdrawn
- 2005-05-16 RU RU2006144093/10A patent/RU2432357C2/ru not_active IP Right Cessation
- 2005-05-16 JP JP2007512595A patent/JP2008506364A/ja not_active Withdrawn
- 2005-05-16 EP EP05748150A patent/EP1745067A2/en not_active Withdrawn
- 2005-05-16 BR BRPI0511118-8A patent/BRPI0511118A/pt not_active Application Discontinuation
- 2005-05-16 EP EP10190386A patent/EP2341069A1/en not_active Withdrawn
- 2005-05-16 EP EP10194789A patent/EP2343313A1/en not_active Withdrawn
- 2005-05-16 US US11/596,557 patent/US7749518B2/en not_active Expired - Fee Related
-
2010
- 2010-05-25 US US12/800,898 patent/US8124098B2/en not_active Expired - Fee Related
-
2011
- 2011-07-29 JP JP2011166505A patent/JP2012000112A/ja active Pending
-
2012
- 2012-01-24 US US13/357,394 patent/US20120148615A1/en not_active Abandoned
-
2014
- 2014-04-29 US US14/264,972 patent/US9102729B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2006144093A (ru) | 2008-06-20 |
EP2351774A1 (en) | 2011-08-03 |
US20080267966A1 (en) | 2008-10-30 |
WO2005111066A2 (en) | 2005-11-24 |
GB0410866D0 (en) | 2004-06-16 |
US8124098B2 (en) | 2012-02-28 |
EP2351773A1 (en) | 2011-08-03 |
EP2343313A1 (en) | 2011-07-13 |
CN1997663A (zh) | 2007-07-11 |
EP2341069A1 (en) | 2011-07-06 |
EP1745067A2 (en) | 2007-01-24 |
US20140234363A1 (en) | 2014-08-21 |
US7749518B2 (en) | 2010-07-06 |
WO2005111066A8 (en) | 2007-05-18 |
BRPI0511118A (pt) | 2007-11-27 |
JP2008506364A (ja) | 2008-03-06 |
US20120148615A1 (en) | 2012-06-14 |
US20100303822A1 (en) | 2010-12-02 |
IN2015KN00290A (ru) | 2015-06-12 |
JP2012000112A (ja) | 2012-01-05 |
WO2005111066A3 (en) | 2006-05-26 |
US9102729B2 (en) | 2015-08-11 |
CA2566632A1 (en) | 2005-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2432357C2 (ru) | ПОЛИПЕПТИДЫ НЕТИПИРУЕМОЙ Haemophilus influenzae | |
RU2007139915A (ru) | Haemophilus influenzae типа в | |
RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
CA2352765A1 (en) | Hapten-carrier conjugates for treating and preventing nicotine addiction | |
EE200200507A (et) | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine | |
RU2008122435A (ru) | Гибридная и тандемная экспрессия белков нейссерий | |
EP2292647A3 (en) | Small Streptococcus pyogenes antigens and their use | |
MX2007003402A (es) | Composicion inmunogena para su uso en vacunacion contra estafilococos. | |
BR0111823A (pt) | Polipeptìdeo, vacina, método para imunizar um animal contra um micróbio patogênico, método para identificar polipeptìdeo antigênicos, anticorpo, ou pelo menos uma parte eficaz deste, vetor, célula, método para a produção do anticorpo, linhagem celular de hibridomas, e, uso dos anticorpos. | |
DE69526339D1 (de) | Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide | |
WO2006065553A3 (en) | Glycoconjugate vaccines containing peptidoglycan | |
DE69635783D1 (de) | Antigen omp26 aus haemophilus influenzae | |
RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
Xie et al. | Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis | |
KR970703164A (ko) | 헬리코박터류 감염의 치료 및 예방용 항원 제제(treatment and prevention of helicobacter infection) | |
WO2005007673A3 (en) | Immunogenic peptides | |
SG144692A1 (en) | Antigenic proteins of shrimp white spot syndrome virus and uses thereof | |
WO2001081380A3 (en) | Immunogenic pneumococcal protein and vaccine compositions thereof | |
JP2002534481A5 (ru) | ||
CA2360382A1 (en) | Use of antibodies for the vaccination against cancer | |
ES2551699T3 (es) | Composiciones, procedimientos y kits | |
EP2982683A1 (en) | Recombinant pasteurella multocida toxin and application thereof | |
KR920004422A (ko) | Hiv의 주요 중화 결정인자 | |
SG128482A1 (en) | Method and composition for altering a b cell mediated pathology | |
RU2015125699A (ru) | Антигены и комбинации антигенов pseudomonas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180517 |